Definitive Healthcare Corp. filed its Q3 2026 Form 10-Q reporting 107,163,253 shares of Class A common stock outstanding as of November 2, 2026. The report highlights key operational risks including dependence on third-party data, the transition of its Chief Executive Officer, and potential transactions involving Advent International.
Definitive Healthcare reported Q3 2026 revenue of $54.7 million, a 9% decrease year-over-year, while narrowing its net loss to $5.4 million. The company noted it will not provide forward guidance or host an earnings call due to a pending non-binding acquisition proposal from Advent International.
Term
Q3 2026
“Since joining Definitive, I’ve been focused on listening to our customers and our employees. What I’ve heard confirms my belief in the strength of our position in the market, and it has also shown me where we can execute better. This quarter’s results demonstrate the underlying health of the business and a solid foundation to build upon.”